Aequus Extends Commercial Agreement for Specialty Product Tacrolimus IR in Canada

VANCOUVER, B.C. – Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”), announced today that it has agreed to an extension of terms for its promotional service agreement with Sandoz on Tacrolimus immediate-release (“Tacrolimus IR”) to December 31st, 2022. Aequus began Canadian promotional efforts in 2016 for Sandoz’s generic Tacrolimus.  Through targeted awareness, valued added services, and customized support for both provincial and transplant centre stakeholders, Aequus has achieved a 4-Year CAGR of almost 20% for the Sandoz Tacrolimus brand.

“Despite the challenges of the pandemic, Aequus Pharma has succeeded in providing a cost-effective and high-quality solution to meet both patient and physician needs,” said Grant Larsen, Chief Commercial Officer of Aequus Pharma.

“This extension of terms reaffirms our commercial capabilities and ability to rejuvenate specialty products and categories for our partners. We look forward to expanding our partnership with Sandoz and bringing added value to both physicians and patients across Canada.” said Doug Janzen, CEO and Chairman of Aequus.

Approved Clinical Uses of Tacrolimus IR in Canada.

The following information is based on the Product Monograph for tacrolimus IR. Please refer to the full Product Monograph for all labeled safety information for tacrolimus IR.

TRANSPLANTATION

• Prophylaxis of organ rejection in patients receiving allogeneic liver, kidney, or heart transplants.
• Treatment of refractory rejection in patients receiving allogeneic liver or kidney transplants.

Tacrolimus is to be used concomitantly with adrenal corticosteroids and other immunosuppressive agents. The safety and efficacy of the use of tacrolimus with sirolimus has not been established.

Only physicians experienced in immunosuppressive therapy and management of organ transplant should prescribe tacrolimus. Patients receiving the drug should be managed in facilities equipped and staffed with adequate laboratory and supportive medical resources. The physician responsible for maintenance therapy should have complete information requisite for the follow-up of the patient.

RHEUMATOID ARTHRITIS

• Treatment of active rheumatoid arthritis in adult patients for whom disease modifying anti-rheumatic drug (DMARD) therapy is ineffective or inappropriate

Tacrolimus may be used as monotherapy or in combination with non-steroidal anti- inflammatory drugs (NSAIDs) and/or steroids, although the possibility of increased toxicity has not been fully explored.

About Aequus Pharmaceuticals Inc.

Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) is a growing specialty pharmaceutical company focused on developing and commercializing high quality, differentiated products. Aequus has grown its sales and marketing efforts to include several commercial products in ophthalmology and transplant. Aequus plans to build on its Canadian commercial platform through the launch of additional products that are either created internally or brought in through an acquisition or license, remaining focused on highly specialized therapeutic areas.

Original source here.